Hepatiq, Inc. is a leading innovator focused on diagnosing the severity of liver disease. Chronic liver disease (CLD) is a slow and silent killer. It is widespread with about 15% prevalence. About 32,000 people die each year in the US from liver disease.
LIVER DISEASE: Injury to the liver (from infections, alcohol, tumors and fat buildup) leads to scar tissue (“fibrosis”) that can reduce liver function. However, the liver has the ability to regenerate thus mitigating the damage. The amount of liver function remaining is determined by the net effect of fibrogenesis and regeneration. It is the residual liver function that determines disease outcomes. Measuring fibrosis alone is not enough!
PRODUCT: HEPATIQ is a software program that measures liver function. This is essential for therapy planning and predicting adverse outcomes including liver transplantation. HEPATIQ provides 3 indices of disease severity - PHM, fSV and fLV. These indices identify patients at risk for future decompensation, and patients with adequate hepatic reserve who would have benign outcomes. Patients with low PHM have a 15-fold increase in risk for hepatic decompensation or liver-related death.
VALIDATION: The PHM index was proven to predict clinical outcomes in the prospective 7-year multi-center HALT-C trial. PHM outperformed standard blood tests and liver biopsies in predicting clinical outcomes. PHM was also shown to track liver function regeneration after an adult-to-adult live donor liver transplant in the A2ALL study.
COMPETITION: Standard blood tests are affected by many factors and don't predict clinical outcomes. The HALT-C trial showed that blood tests were normal in patients who later had adverse outcomes. Liver biopsy measures fibrosis (not function), is invasive, costly, and subject to error as only a small piece of a large organ is sampled. Ultrasound based tests are also measuring fibrosis and not function!
MARKET: Chronic liver disease (CLD) is a slow and silent killer affecting 1+ billion people. About 32,000 people die each year in the US from CLD. The cost of treating CLD patients is about $40,000 per patient per year. Potential customers for HEPATIQ are 29,000 hospitals and imaging centers globally. The total reachable market is $10+ billion/year.
TECHNOLOGY: HEPATIQ analyzes SPECT nuclear medicine images to determine PHM, fSV and fLV. It is covered by US Patent 9,155,513 and Trademarks 4,810,355, 5,161,483, 5,087,845, 5,087,844, 5,083,571 and 5,018,662. The FDA has cleared it for sale via K142891 and K161188.
REVENUES: Customers receive $1,200+ per HEPATIQ test under CPT 78205. They use existing scanners and need no capital investment. We offer a free trial to encourage adoption. Once adopted, we charge $95 per test. We now have recurring revenues from paying customers.
For more information, please visit www.hepatiq.com or contact:
Dipu Ghosh, MSEE, MBA.
Chief Executive Officer